Caribou Biosciences (CRBU) Non-Current Assets (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Non-Current Assets data on file, last reported at $26.6 million in Q1 2026.

• Quarterly Non-Current Assets fell 52.75% year-over-year to $26.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $124.6 million (down 65.31% YoY) and the FY2025 annual result came in at $30.1 million, down 67.92% from the prior year.
• Non-Current Assets retreated to $26.6 million in Q1 2026 per CRBU's latest filing, from $30.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $113.5 million in Q4 2022 and bottomed at $26.6 million in Q1 2026.
• The 5-year median for Non-Current Assets is $91.9 million (2022), against an average of $78.1 million.
• The widest annual swing landed in 2022, when Non-Current Assets surged 611.69%; it then plunged 72.18% in 2025.
• Tracing CRBU's Non-Current Assets over 5 years: stood at $113.5 million in 2022, then dropped by 17.75% to $93.4 million in 2023, then climbed by 0.61% to $93.9 million in 2024, then tumbled by 67.92% to $30.1 million in 2025, then slipped by 11.67% to $26.6 million in 2026.
• Per Business Quant, the three latest CRBU Non-Current Assets figures stand at $26.6 million (Q1 2026), $30.1 million (Q4 2025), and $39.5 million (Q3 2025).

Peer Comparison